225 related articles for article (PubMed ID: 35439167)
21. The Hematopoietic Microenvironment in Myeloproliferative Neoplasms: The Interplay Between Nature (Stem Cells) and Nurture (the Niche).
Zhan H; Kaushansky K
Adv Exp Med Biol; 2020; 1273():135-145. PubMed ID: 33119879
[TBL] [Abstract][Full Text] [Related]
22. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice.
Chagraoui H; Komura E; Tulliez M; Giraudier S; Vainchenker W; Wendling F
Blood; 2002 Nov; 100(10):3495-503. PubMed ID: 12393681
[TBL] [Abstract][Full Text] [Related]
23. Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology.
Eran Z; Zingariello M; Bochicchio MT; Bardelli C; Migliaccio AR
F1000Res; 2019; 8():. PubMed ID: 31583083
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.
Zingariello M; Martelli F; Ciaffoni F; Masiello F; Ghinassi B; D'Amore E; Massa M; Barosi G; Sancillo L; Li X; Goldberg JD; Rana RA; Migliaccio AR
Blood; 2013 Apr; 121(17):3345-63. PubMed ID: 23462118
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor β-mediated micromechanics modulates disease progression in primary myelofibrosis.
Teodorescu P; Pasca S; Jurj A; Gafencu G; Joelsson JP; Selicean S; Moldovan C; Munteanu R; Onaciu A; Tigu AB; Buse M; Zimta AA; Stiufiuc R; Petrushev B; Desmirean M; Dima D; Vlad C; Bergthorsson JT; Berce C; Ciurea S; Ghiaur G; Tomuleasa C
J Cell Mol Med; 2020 Oct; 24(19):11100-11110. PubMed ID: 32889753
[TBL] [Abstract][Full Text] [Related]
26. Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis.
Gleitz HF; Kramann R; Schneider RK
J Pathol; 2018 Jun; 245(2):138-146. PubMed ID: 29570794
[TBL] [Abstract][Full Text] [Related]
27. Canonical Wnt/β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis.
Lucijanic M; Livun A; Tomasovic-Loncaric C; Stoos-Veic T; Pejsa V; Jaksic O; Prka Z; Kusec R
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):523-526. PubMed ID: 27381374
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.
Agarwal A; Morrone K; Bartenstein M; Zhao ZJ; Verma A; Goel S
Stem Cell Investig; 2016; 3():5. PubMed ID: 27358897
[TBL] [Abstract][Full Text] [Related]
29. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
Kaushansky K; Zhan H
Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
[TBL] [Abstract][Full Text] [Related]
30. Evidence for organ-specific stem cell microenvironments.
Ghinassi B; Martelli F; Verrucci M; D'Amore E; Migliaccio G; Vannucchi AM; Hoffman R; Migliaccio AR
J Cell Physiol; 2010 May; 223(2):460-70. PubMed ID: 20112287
[TBL] [Abstract][Full Text] [Related]
31. P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.
Spangrude GJ; Lewandowski D; Martelli F; Marra M; Zingariello M; Sancillo L; Rana RA; Migliaccio AR
Stem Cells; 2016 Jan; 34(1):67-82. PubMed ID: 26439305
[TBL] [Abstract][Full Text] [Related]
32. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor.
Pecquet C; Staerk J; Chaligné R; Goss V; Lee KA; Zhang X; Rush J; Van Hees J; Poirel HA; Scheiff JM; Vainchenker W; Giraudier S; Polakiewicz RD; Constantinescu SN
Blood; 2010 Feb; 115(5):1037-48. PubMed ID: 19996410
[TBL] [Abstract][Full Text] [Related]
33. Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models.
Dutta A; Nath D; Yang Y; Le BT; Rahman MF; Faughnan P; Wang Z; Stuver M; He R; Tan W; Hutchison RE; Foulks JM; Warner SL; Zang C; Mohi G
Leukemia; 2022 Mar; 36(3):746-759. PubMed ID: 34741118
[TBL] [Abstract][Full Text] [Related]
34. [Pathomechanism and clinical impact of myelofibrosis in neoplastic diseases of the bone marrow].
Bedekovics J; Méhes G
Orv Hetil; 2014 Mar; 155(10):367-75. PubMed ID: 24583557
[TBL] [Abstract][Full Text] [Related]
35. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis.
Le Bousse-Kerdilès MC; Martyré MC;
Pathol Biol (Paris); 2001 Mar; 49(2):153-7. PubMed ID: 11317961
[TBL] [Abstract][Full Text] [Related]
36. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis.
Pizzi M; Gergis U; Chaviano F; Orazi A
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):96-104. PubMed ID: 27521149
[TBL] [Abstract][Full Text] [Related]
37. Deposition of transforming growth factor-beta in the marrow in myelofibrosis, and the intracellular localization and secretion of TGF-beta by leukemic cells.
Johnston JB; Dalal BI; Israels SJ; Oh S; McMillan E; Begleiter A; Michaud G; Israels LG; Greenberg AH
Am J Clin Pathol; 1995 May; 103(5):574-82. PubMed ID: 7741102
[TBL] [Abstract][Full Text] [Related]
38. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
Martyré MC
Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
[TBL] [Abstract][Full Text] [Related]
39. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis.
Vannucchi AM; Bianchi L; Paoletti F; Pancrazzi A; Torre E; Nishikawa M; Zingariello M; Di Baldassarre A; Rana RA; Lorenzini R; Alfani E; Migliaccio G; Migliaccio AR
Blood; 2005 May; 105(9):3493-501. PubMed ID: 15665119
[TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor β- and interleukin 13-producing mast cells are associated with fibrosis in bone marrow.
Nakayama S; Yokote T; Hiraoka N; Akioka T; Nishiwaki U; Miyoshi T; Iwaki K; Fumimoto A; Masuda Y; Hatooka J; Fujimoto M; Nishimura Y; Tsuji M
Hum Pathol; 2017 Apr; 62():180-186. PubMed ID: 28159675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]